Bocidelpar sulfate is under clinical development by Mitobridge and currently in the Phase I and Phase III in clinical pathway. The characteristics of the clinical trial as well as other attributes related to the drug, regulations, and company play a fundamental role in ensuring the likelihood of transition that the drug moves from its current development stage to next.
According to GlobalData, the latest event to affect Bocidelpar sulfate’s likelihood of approval (LoA) and phase transition for MELAS Syndrome (Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-Like Episodes) took place on 09 Feb 2022, which increased the likelihood that the drug progresses to the next phase in its clinical pathway.
GlobalData uses proprietary data and analytics to provide a complete picture of this assessment in their Bocidelpar sulfate Likelihood of Approval (LoA) and Phase Transition Success Rate (PTSR) Report.
Bocidelpar sulfate overview
MA-0211 is under development for the treatment of Duchenne muscular dystrophy (DMD), mitochondrial myopathies and fatty acid oxidation disorders including Melas syndrome, Kearns-Sayre syndrome. It is administered through oral route. The drug candidate acts by targeting peroxisome proliferator-activated receptor delta (PPARdelta). It was also under development for Leber’s hereditary optic neuropathy (LHON).
Mitobridge, formerly Mitokyne, a subsidiary of Astellas Pharma Inc is a drug development company. It discovers and develops small molecule therapeutics that recovers mitochondrial functions. The company develops therapies for rare diseases and expands into more common diseases. Mitobridge utilizes screening platform to identify and develop novel therapeutics. In addition, The company holds expertise in the areas of mitochondrial genetic diseases, musculoskeletal, liver disease, kidney, neurodegenerative disorders and diseases and conditions of aging. It works in collaboration with companies in the field of mitochondrial biology and medicine. Mitobridge is headquartered in Cambridge, Massachusetts, the US.
Quick View Bocidelpar sulfate LOA Data
|Highest Development Stage|